Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Association of Snowfall and Myocardial Infarction

Condition:   Acute Myocardial Infarction
Intervention:   Other: snowfall > 5cm/day
Sponsor:   Medical University of Graz
Active, not recruiting - verified September 2016

Women's Heart Attack Research Program: Stress Ancillary Study

Condition:   Myocardial Infarction
Interventions:   Behavioral: Enhanced Usual Care;   Behavioral: Stress Management;   Device: Actigraph
Sponsor:   New York University School of Medicine
Recruiting - verified September 2016

The SORT OUT IX STEMI OCT Trial

Condition:   Acute Myocardial Infarction
Interventions:   Device: BioFreedom;   Device: Orsiro
Sponsors:   Odense University Hospital;   Aarhus University Hospital;   Rigshospitalet, Denmark
Not yet recruiting - verified September 2016

Frailty as an INstrument for Evaluation of Elderly Patients With Non ST ElevationMyocardial Infarction (NSTEMI) - 5 Year Follow up

Conditions:   Non ST Elevation Myocardial Infarction (NSTEMI);   Frailty
Intervention:   Other: This is an observational study
Sponsor:   Linkoeping University
Not yet recruiting - verified September 2016

Women's Heart Attack Research Program- Imaging Study

Condition:   Myocardial Infarction
Interventions:   Device: OCT;   Other: CMR
Sponsor:   New York University School of Medicine
Recruiting - verified September 2016

Phase I Study of Bone Marrow Derived Mononuclear Cells to Right Ventricle of Patients With Ebstein Anomaly

Condition:   Ebstein Anomaly
Interventions:   Biological: Autologous Bone Marrow-derived Mononuclear Cells;   Device: Insertable cardiac monitor
Sponsor:   Timothy J. Nelson
Not yet recruiting - verified September 2016

Effects of Morphine on Loading-dose Ticagrelor in Patients With ST-segment Elevation Myocardial Infarction

Condition:   ST-segment Elevation Myocardial Infarction
Interventions:   Drug: Morphine;   Drug: metoclopramide;   Drug: saline
Sponsor:   General Hospital of Chinese Armed Police Forces
Recruiting - verified September 2016

Bivalirudin in Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Drug: Bivalirudin;   Drug: heparin
Sponsor:   Shenzhen Salubris Pharmaceuticals Co., Ltd.
Not yet recruiting - verified September 2016

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

Conditions:   Prediabetic State;   Atherosclerosis;   Metformin
Interventions:   Drug: Metformin XR;   Drug: Placebo
Sponsor:   VA Office of Research and Development
Not yet recruiting - verified September 2016

Coroflex ISAR 2000 Extended Registry (ISAR2000 Extended)

Condition:   Coronary Artery Disease (CAD)
Intervention:   Device: stenting with the Coroflex ISAR sirolimus-eluting stent
Sponsors:   B. Braun Melsungen AG;   Charite University, Berlin, Germany
Recruiting - verified September 2016

Use of Public Health Surveillance Models in the French National Health System Database

Conditions:   Atrial Fibrillation;   Anticoagulants;   Pharmacoepidemiology
Intervention:   Drug: Dabigatran
Sponsor:   Centre Hospitalier Universitaire de la Réunion
Recruiting - verified September 2016

Acute Coronary Syndrome Sri Lanka Audit Project

Conditions:   Acute Coronary Syndrome;   Unstable Angina;   Non ST Elevation Myocardial Infarction;   ST Elevation Myocardial Infarction
Intervention:   Drug: aspirin, clopidogrel, statin, enoxaparin, streptokinase
Sponsors:   University of Colombo;   Ministry of Health, Sri Lanka
Withdrawn - verified September 2016

MOMENTUM 3 Continued Access Protocol

Condition:   Advanced Refractory Left Ventricular Heart Failure
Intervention:   Device: HeartMate 3 LVAS
Sponsors:   St. Jude Medical;   Thoratec, LLC
Recruiting - verified September 2016

Outdoor Walking and Strength Training After Acute Stroke or Transient Ischemic Attack.

Conditions:   Acute Stroke;   TIA (Transient Ischemic Attack)
Intervention:   Other: Outdoor walking and strength exercise
Sponsor:   Uppsala County Council, Sweden
Not yet recruiting - verified September 2016

Efficacy of Furosemide Versus Vascular Filling in Patients With Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction With Right Ventricular Extension
Interventions:   Drug: Furosemide;   Drug: Placebo filling;   Drug: Placebo furosemide;   Drug: Vascular filling
Sponsor:   Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified July 2016

Safety and Efficacy of IV TXA in Reducing Blood Loss and Transfusion in Hip Fractures

Conditions:   Hip Fractures;   Blood Loss
Interventions:   Drug: Tranexamic Acid;   Drug: Placebo
Sponsor:   Yale University
Not yet recruiting - verified September 2016

STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction

Condition:   Myocardial Infarction
Interventions:   Drug: Tenecteplase;   Drug: Clopidogrel;   Procedure: Coronary angiography;   Procedure: Primary PCI
Sponsors:   Katholieke Universiteit Leuven;   Boehringer Ingelheim;   Life Sciences Research Partners;   Fund for Clinical Cardiovascular Research at LRD
Not yet recruiting - verified September 2016

Platelet Function in Resuscitated Patients

Condition:   Acute ST Segment Elevation Myocardial Infarction
Intervention:   Other: diagnostic analysis of platelet function
Sponsor:   Medical University of Graz
Completed - verified September 2016

The Wire-free Invasive Functional Imaging (WIFI) Study

Condition:   Coronary Artery Disease
Intervention:   Other: QFR (observational)
Sponsor:   Niels Ramsing Holm
Recruiting - verified September 2016

The Impact of Opioids in Coronary Heart Disease

Condition:   Coronary Heart Disease
Intervention:  
Sponsors:   Ruhr University of Bochum;   Mundipharma Research GmbH & Co KG
Completed - verified September 2016

STAT-STatin and Aspirin in Trauma

Conditions:   Wounds and Injuries;   Venous Thromboembolism
Interventions:   Drug: Aspirin and Rosuvastatin;   Drug: Placebo (for Aspirin and Rosuvastatin)
Sponsor:   Denver Health and Hospital Authority
Not yet recruiting - verified September 2016

Remote Ischaemic Conditioning After Stroke Trial (ReCAST-2)

Condition:   Stroke
Interventions:   Procedure: Remote ischaemic conditioning;   Procedure: Sham
Sponsor:   University of Nottingham
Recruiting - verified September 2016

Coroflex ISAR 2000 Registry

Condition:   Coronary Artery Disease (CAD)
Intervention:   Device: stenting with the Coroflex ISAR sirolimus-eluting stent
Sponsors:   B. Braun Melsungen AG;   Charite University, Berlin, Germany
Active, not recruiting - verified September 2016

BIOFREEDOM Stent Versus ORSIRO Stent: SORT OUT IX

Condition:   Ischaemic Heart Disease
Interventions:   Device: Biofreedom;   Device: Orsiro
Sponsors:   Odense University Hospital;   Aarhus University Hospital Skejby;   Aalborg Universitetshospital;   Rigshospitalet, Denmark
Recruiting - verified September 2016

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial

Conditions:   Stable Angina;   Unstable Angina;   Non-ST Segment Elevation Myocardial Infarction
Interventions:   Device: CX-ISAR;   Device: Orsiro;   Drug: 3-months DAPT;   Drug: 1-year DAPT
Sponsors:   Seoul National University Hospital;   B. Braun Korea Co., Ltd.
Recruiting - verified September 2016

Vorapaxar as an Add-On Antiplatelet Therapy in Post Myocardial Infarction Patients With and Without Diabetes Mellitus

Conditions:   Myocardial Infarction;   Diabetes Mellitus
Interventions:   Drug: Vorapaxar;   Drug: Clopidogrel;   Drug: Aspirin
Sponsors:   University of Florida;   Merck Sharp & Dohme Corp.
Recruiting - verified September 2016

Phase I Safety and Feasibility Study of Intracoronary Delivery of Autologous Bone Marrow Derived Mononuclear Cells

Condition:   Congenital Heart Disease
Intervention:   Biological: Autologous Bone Marrow-derived Mononuclear Cells
Sponsor:   Timothy J. Nelson
Recruiting - verified September 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified September 2016

Frail Status of Elderly Patients After Repair and Anesthesia Guided by the bispectraL Index

Conditions:   Anesthesia, General;   Aged, 70 and Over
Interventions:   Other: Toolbox: Automated group;   Other: Manual group
Sponsor:   Hopital Foch
Recruiting - verified September 2016

Examining How Acute Treatment Contributes to Variations in AMI Mortality Across the English NHS

Condition:   Myocardial Infarction
Intervention:   Other: Standard Hospital Care
Sponsor:   London School of Economics and Political Science
Active, not recruiting - verified September 2016

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified September 2016

Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia

Conditions:   Complex Endometrial Hyperplasia With Atypia;   Stage IA Uterine Corpus Cancer;   Stage IB Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer
Interventions:   Behavioral: Weight Loss Specialist;   Other: Quality-of-Life Assessment;   Other: Medical Chart Review
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified September 2016

Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART

Conditions:   ST-segment Elevation Myocardial Infarction;   Non ST-segment Elevation Myocardial Infarction
Interventions:   Drug: bivalirudin;   Drug: Heparin
Sponsors:   Uppsala University;   Lund University
Active, not recruiting - verified September 2016

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Active, not recruiting - verified September 2016

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified September 2016

Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

Conditions:   Transient Ischemic Attack;   Stroke;   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Warfarin
Sponsors:   University of South Florida;   Bristol-Myers Squibb
Recruiting - verified September 2016

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified September 2016

Consistent CTO Trial

Condition:   Chronic Total Occlusion
Intervention:   Device: Percutaneous coronary intervention
Sponsors:   European Cardiovascular Research Center;   Ceric Sàrl
Recruiting - verified September 2016

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified September 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified September 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified September 2016

Xanthine Oxidase Inhibition for Improvement of Long-term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack

Condition:   Ischaemic Stroke
Interventions:   Drug: Allopurinol;   Drug: Placebo
Sponsors:   NHS Greater Glasgow and Clyde;   University of Glasgow
Recruiting - verified September 2016

The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH

Conditions:   Diabetes;   Chronic Kidney Disease;   Established Atherosclerotic Vascular Disease;   Framingham Risk Score >20%
Intervention:   Other: Advanced Care
Sponsors:   University of Alberta;   Alberta Health & Wellness;   Alberta Health Services;   Merck Frosst Canada Ltd.
Completed - verified September 2016

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified September 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified September 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified September 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified September 2016

GLORIA-AF Registry Program (Phase II/III)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified September 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified September 2016

Application for Self-Monitoring of Cardiovascular Risk

Condition:   Coronary Disease
Intervention:   Device: Self Monitoring Software Application
Sponsor:   Mayo Clinic
Completed - verified September 2016

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

Conditions:   MDS (Myelodysplastic Syndrome);   Myeloproliferative Disorder;   Lymphoma, Non-Hodgkin;   ALL (Acute B-Lymphoblastic Leukemia);   AML (Acute Meylogenous Leukemia
Intervention:   Device: Graft Manipulation (CD34+ Selection)
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Children's Research Institute
Recruiting - verified September 2016

Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent

Conditions:   Coronary Artery Disease;   Ischemic Heart Disease
Intervention:   Device: Drug-eluting stent
Sponsor:   Odense University Hospital
Active, not recruiting - verified September 2016

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: rivaroxaban 2.5 mg;   Drug: rivaroxaban 15 mg;   Drug: rivaroxaban 10 mg;   Drug: aspirin (ASA);   Drug: vitamin K antagonist (VKA);   Drug: clopidogrel;   Drug: prasugrel;   Drug: ticagrelor
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer
Completed - verified September 2016

Cooling in Myocardial Infarction

Condition:   ST-elevation Myocardial Infarction
Intervention:   Device: EMCOOLS flex pad; Philips Innercool RTx
Sponsors:   Medical University of Vienna;   Austrian Science Fund (FWF)
Active, not recruiting - verified September 2016

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention &Amp; Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute
Recruiting - verified September 2016

Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in MyoCardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Other: 12.5 M Mesenchymal Precursor Cells (MPC);   Other: Placebo;   Other: 25M Mesenchymal Precursor Cells (MPC)
Sponsors:   Mesoblast, Ltd.;   Teva Pharmaceuticals USA
Active, not recruiting - verified September 2016

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   High Risk for Cardiovascular Event
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Placebo tablet
Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   The TIMI Study Group;   Hadassah Medical Organization
Active, not recruiting - verified September 2016

STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial

Conditions:   Intracerebral Haemorrhage;   Stroke
Interventions:   Drug: Tranexamic Acid;   Drug: Placebo
Sponsor:   Neuroscience Trials Australia
Recruiting - verified September 2016

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab;   Drug: Placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified September 2016

Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.

Conditions:   Philadelphia Positive;   BCR-ABL Positive;   Acute Lymphoblastic Leukemia
Intervention:   Drug: Ponatinib
Sponsor:   Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified September 2016

Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)

Conditions:   Thrombosis;   Coronary Artery Disease
Interventions:   Drug: Prasugrel;   Drug: Clopidogrel
Sponsor:   Indiana University
Terminated - verified September 2016

The Nordic-Baltic Bifurcation Study IV

Condition:   Coronary Artery Disease
Interventions:   Procedure: Implantation of coronary stent in bifurcation lesion;   Procedure: Implantation of coronary stent in bifurcation lesion
Sponsors:   Niels Ramsing Holm;   Johnson & Johnson
Active, not recruiting - verified September 2016

Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration

Condition:   Myocardial Infarction
Intervention:   Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells
Sponsors:   Capricor Inc.;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI);   California Institute for Regenerative Medicine (CIRM)
Recruiting - verified September 2016

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified September 2016

Clinical Randomisation of an Antifibrinolytic in Significant Head Injury

Condition:   Traumatic Brain Injury
Intervention:   Drug: Tranexamic Acid
Sponsor:   London School of Hygiene and Tropical Medicine
Recruiting - verified September 2016

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

Condition:   Non-ischemic Dilated Cardiomyopathy
Interventions:   Procedure: Transendocardial injection;   Biological: Autologous hMSCs;   Biological: Allogeneic hMSCs
Sponsors:   Joshua M Hare;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified September 2016

Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis

Conditions:   Hypertrophic Cardiomyopathy;   Acute Coronary Syndrome
Intervention:   Radiation: 99mTc-NC100692
Sponsor:   Ottawa Heart Institute Research Corporation
Recruiting - verified September 2016

Systolic Blood Pressure Intervention Trial

Condition:   Hypertension
Interventions:   Other: Intensive control of SBP;   Other: Standard BP arm
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Institute on Aging (NIA);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute of Neurological Disorders and Stroke (NINDS);   Wake Forest Baptist Health
Active, not recruiting - verified September 2016

Morphine In Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Drug: morphine chlorhydrate;   Drug: saline solution
Sponsors:   French Cardiology Society;   Institut National de la Santé Et de la Recherche Médicale, France
Active, not recruiting - verified June 2016

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Condition:   Ankylosing Spondylitis
Intervention:  
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified September 2016

Intramyocardial Transplantation of Bone Marrow Stem Cells in Addition to Coronary Artery Bypass Graft (CABG) Surgery

Conditions:   Myocardial Ischemia;   Coronary Artery Disease
Interventions:   Drug: CD133+ autologous bone marrow stem cell;   Drug: Placebo
Sponsors:   Miltenyi Biotec GmbH;   German Federal Ministry of Education and Research
Terminated - verified September 2016

The Nordic Bifurcation Study III

Condition:   Coronary Artery Disease
Intervention:   Procedure: Percutaneous coronary intervention (PCI)
Sponsors:   Niels Ramsing Holm;   Johnson & Johnson
Active, not recruiting - verified September 2016

Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

Condition:   Myocardial Infarction
Interventions:   Drug: Prochymal®;   Drug: Placebo
Sponsor:   Mesoblast International Sàrl
Completed - verified September 2016

Study of Women With Acute Coronary Syndromes and Nonobstructive Coronary Artery Disease

Condition:   Acute Coronary Syndromes
Interventions:   Procedure: Intravascular ultrasound;   Procedure: MRI
Sponsors:   New York University School of Medicine;   Doris Duke Charitable Foundation
Active, not recruiting - verified September 2016

Model System for Transient Forearm Blood Vessel Dysfunction

Conditions:   Limb Ischemia;   Ischemic Preconditioning
Interventions:   Procedure: Limb Ischemia;   Drug: Acetylcholine
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2009

HEROIC (Heparin Requirement in Counterpulsation)

Condition:   Cardiogenic Shock
Interventions:   Drug: Heparin;   Other: Without Heparin
Sponsor:   Justin Trivax
Completed - verified September 2016

Nordic Bifurcation Study. How to Use Drug Eluting Stents (DES) in Bifurcation Lesions?

Condition:   Coronary Artery Disease
Intervention:   Procedure: Percutaneous coronary intervention
Sponsors:   Aarhus University Hospital Skejby;   Johnson & Johnson
Completed - verified September 2016

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Conditions:   Lymphoma;   Leukemia;   Myeloproliferative Disorders;   Multiple Myleoma;   Myelodysplastic Syndrome
Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Procedure: PBSC transplantation;   Genetic: T cell DLI with sirolimus generated donor TH-2 cells;   Drug: Prednisone;   Procedure: Allogeneic HSCT;   Drug: Filgrastim;   Genetic: T-Rapa cell DLI
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified September 2016

Nordic Bifurcation Stent Technique Study (BIF II)

Condition:   Coronary Artery Disease
Intervention:   Procedure: Percutaneous coronary intervention
Sponsors:   Aarhus University Hospital Skejby;   Cordis Corporation
Completed - verified September 2016

Michelangelo - Oasis 5

Condition:   Thromboembolism
Interventions:   Drug: Fondaparinux;   Drug: enoxaparin
Sponsors:   GlaxoSmithKline;   University of Chicago;   Organon;   Sanofi;   Duke University
Completed - verified September 2016

OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction

Condition:   Thromboembolism
Interventions:   Drug: fondaparinux - UFH not indicated;   Other: Control - UFH not indicated;   Drug: Fondaparinux - UFH indicated;   Drug: Control - UFH
Sponsors:   GlaxoSmithKline;   Sanofi
Completed - verified September 2016

Technical Development of Cardiovascular Magnetic Resonance Imaging

Condition:   Cardiovascular Disease
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified September 2016